A Prospective Clinical Investigation of DMFI300 for Treating Nasolabial Folds (NCT07467239) | Clinical Trial Compass
RecruitingNot Applicable
A Prospective Clinical Investigation of DMFI300 for Treating Nasolabial Folds
Spain30 participantsStarted 2026-03-02
Plain-language summary
This is a prospective, randomized, controlled clinical investigation designed to evaluate the performance and safety of DMFI300 for the treatment of nasolabial folds. 30 adult participants will receive treatment with the investigational device and the comparator device using a split-face design. The study will assess wrinkle severity using validated aesthetic evaluation scales, as well as overall safety.
Who can participate
Age range18 Years – 70 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Men and women aged 18-70 years.
* Score of 3 to 4 on the Wrinkle Severity Rating Scale (WSRS) for both nasolabial folds.
* Willing and able to provide written informed consent.
* Willing to comply with study procedures and follow-up visits.
* Willing to refrain from other facial cosmetic procedures affecting the nasolabial folds during the study.
Exclusion Criteria:
* Use of antiplatelet agents, vitamin E, or NSAIDs within 2 weeks before screening or planned use within 2 weeks after treatment.
* History or presence of bleeding disorders.
* Participation in another clinical investigation within 1 month prior to screening.
* Pregnant or breastfeeding women, or women planning pregnancy during the study.
* Women of childbearing potential not using an effective method of contraception.
What they're measuring
1
Change from Baseline in Wrinkle Severity Rating Scale (WSRS) as Assessed by the Evaluating Investigator (EI)